UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

17 UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Read More Share:

Apr

14 Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

Read More Share:

Apr

13 UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Read More Share:

Mar

31 Employee Spotlight: Judith Thompson’s Journey to Making a Larger Impact through Addressing Health Disparities for People Living with Severe Diseases

Read More Share:

Mar

18 Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Read More Share:

Mar

17 Exploring the future of dermatology at AAD 2023

Read More Share:

Mar

16 You Speak, We Listen: How Community Voices Drive Our Work in HS

Read More Share:

Mar

16 UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Read More Share:

Mar

15 Building a Community of Trust in Epilepsy & Rare Syndromes

Read More Share:

Feb

23 Voices on Value: Building a Sustainable Healthcare System for a Healthier Tomorrow – The Second Annual U.S. Sustainable Access and Pricing Transparency Report

Read More Share:

Categories

Archives

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Apr

14

Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

Apr

13

UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Mar

31

Employee Spotlight: Judith Thompson’s Journey to Making a Larger Impact through Addressing Health Disparities for People Living with Severe Diseases

Mar

18

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Mar

17

Exploring the future of dermatology at AAD 2023

Mar

16

You Speak, We Listen: How Community Voices Drive Our Work in HS

Mar

16

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Mar

15

Building a Community of Trust in Epilepsy & Rare Syndromes

Feb

23

Voices on Value: Building a Sustainable Healthcare System for a Healthier Tomorrow – The Second Annual U.S. Sustainable Access and Pricing Transparency Report

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Categories

Archives

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Apr

14

Recognizing UCB’s Rising Stars: Brittany Blair and Lauren Drowley Recognized by the Healthcare Businesswomen’s Association

Apr

13

UCB’s Commitment to Understanding Sudden Unexpected Death in Epilepsy (SUDEP)

Mar

31

Employee Spotlight: Judith Thompson’s Journey to Making a Larger Impact through Addressing Health Disparities for People Living with Severe Diseases

Mar

18

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Mar

17

Exploring the future of dermatology at AAD 2023

Mar

16

You Speak, We Listen: How Community Voices Drive Our Work in HS

Mar

16

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Mar

15

Building a Community of Trust in Epilepsy & Rare Syndromes

Feb

23

Voices on Value: Building a Sustainable Healthcare System for a Healthier Tomorrow – The Second Annual U.S. Sustainable Access and Pricing Transparency Report

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact